Author:
Park Yong-Jin,Im Yunjoo,Kwon O. Jung,Han Joungho,Ahn Myung-Ju,Kim Jhingook,Um Sang-Won,Choi Joon Young
Abstract
AbstractPulmonary lymphangitic carcinomatosis (PLC) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). We sought to determine prognostic value of pretherapeutic fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in NSCLC with radiologically diagnosed PLC. We retrospectively reviewed 50 NSCLC patients with radiologically diagnosed PLC. Among eight clinical variables and five imaging parameters, metabolic PLC burden, which represents the overall tumor burden of PLC, and cPLC, which represents the location and extent of PLC in a three-grade system, were used. In multivariate analyses for progression-free survival, metabolic PLC burden (P = 0.0181), cPLC (P = 0.0401), and clinical stage (P = 0.0284) were identified as independent prognostic factors. High metabolic PLC burden had a worse prognosis, and the prognosis of cPLC3 was significantly worse than that of cPLC1 or cPLC2. In univariate analyses for overall survival, only age (P = 0.0073) was identified a prognostic factor. In conclusion, FDG PET/CT parameters were identified as independent prognostic factors in NSCLC with radiologically diagnosed PLC. Furthermore, a combination of anatomical and metabolic information about PLC obtained using FDG PET/CT provides insight into the overall tumor burden of PLC and is useful in predicting prognosis.
Funder
National Research Foundation of Korea (NRF) grant funded by the Korea government
Future Medicine 20*30 Project of the Samsung Medical Center
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Lee, D. S. et al. Distinctive patterns of initially presenting metastases and clinical outcomes according to the histological subtypes in stage IV non-small cell lung cancer. Medicine (Baltimore) 95, e2795. https://doi.org/10.1097/md.0000000000002795 (2016).
2. Im, Y. et al. Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer. Transl. Lung Cancer Res. 10, 4130–4140. https://doi.org/10.21037/tlcr-21-677 (2021).
3. Ooi, H., Chen, C. Y., Hsiao, Y. C., Huang, W. S. & Hsieh, B. T. Fluorodeoxyglucose uptake in advanced non-small cell lung cancer with and without pulmonary lymphangitic carcinomatosis. Anticancer Res. 36, 4313–4320 (2016).
4. Jreige, M. et al. Pulmonary lymphangitic carcinomatosis: Diagnostic performance of high-resolution CT and (18)F-FDG PET/CT in correlation with clinical pathologic outcome. J. Nucl. Med. 61, 26–32. https://doi.org/10.2967/jnumed.119.229575 (2020).
5. Acikgoz, G. et al. Pulmonary lymphangitic carcinomatosis (PLC): Spectrum of FDG-PET findings. Clin. Nucl. Med. 31, 673–678. https://doi.org/10.1097/01.rlu.0000242210.99022.fd (2006).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献